29 Oct Pantherna Therapeutics Secures New Patent Grant in the United States of America
Hennigsdorf, Germany
Pantherna Therapeutics GmbH, a leading innovator in advanced LNP technologies for mRNA-based therapeutics, is pleased to announce the upcoming grant of US-Patent application No. 17/173,109, titled “Recombinant Nucleic Acid Construct,”
The forthcoming U.S. patent will further strengthen Pantherna’s global intellectual property position and safeguard its PTXmRNA® technology, which facilitates efficient and enduring protein expression in therapeutic applications. Securing patent protection in the United States, a significant market for mRNA and gene therapy innovation, underscores the broad applicability and pioneering nature of Pantherna’s technology.
Dr. Jörg Kaufmann, Chief Scientific Officer of Pantherna Therapeutics, asserted, “Securing Patent protection in the United States, in conjunction with our existing patents in Canada, Europe, Japan, and Korea, underscores the transformative potential of our PTXmRNA® technology. This recognition enhances our standing as a prospective commercial partner for collaborative research and licensing endeavors in these global markets focused on mRNA-based therapies.”